Document is current

Article History

Received: 3 April 2025

Accepted: 20 August 2025

First Online: 2 September 2025

Declarations

:

: H. Goto reports lecture fees earned from Kyowa Kirin, Vie, Chugai, Novartis, Bristol Myers Squibb, Gilead and research funding from Kyowa Kirin, Gilead and Bristol Myers Squibb. S. Ito reports research funding from IQVIA, Meiji Seika Pharma, MSD, AstraZeneca, Abbvie, Amgen, Incyte, Otsuka, Gilead, Syneos Health Japan, Sanofi, Novartis, Zenyaku, Mitsubishi Tanabe, Chugai, Eli Lilly, Novartis, Bayer, Parexel, Pfizer, Bristol and Janssen. M. Kizaki has nothing to disclose. M. Yamaguchi has nothing to disclose. N. Fukuhara reports research funding from AbbVie, Bayer, Celgene, Chordia Therapeutics, Chugai, Genmab, Incyte, Kyowa-Kirin, LOXO Oncology, and Takeda. K. Kato reports research funding from AbbVie, Bristol Myers Squibb, Chugai, Daiichi Sankyo, Eisai, Janssen, Kyowa Kirin, Novartis, and Takeda. T. Saito reports research funding from AbbVie and Meiji Seika Pharma Co. Y. Terui reports lecture fees earned from AbbVie, Celgene, Chugai, Eisai, Janssen, Ono, and Symbio and contribution from Eisai. T. Soshin reports her and her husband’s employment with AbbVie and may hold stock options or other ownership in AbbVie. N. Satomi reports employment with AbbVie and may hold stock options or other ownership in AbbVie. H. Honda reports employment with AbbVie and may hold stock options or other ownership in AbbVie. C. Qian reports employment with AbbVie and may hold stock options or other ownership in AbbVie. K. Izutsu reports consulting, research funding, and honoraria fees from AbbVie; honoraria and research funding from Janssen, Chugai, AstraZeneca, and Bristol Myers Squibb; and honoraria from Eli Lilly and Zenyaku.